HCA is procuring a vendor for PDL development and once finalized, more information will be posted here
Pharmacy and Therapeutics (P&T) and Drug Utilization Review (DUR) Committee
In 2026 New Mexico Health Care Authority will implement a statewide Preferred Drug List (PDL) designed to streamline medication access for Medicaid members and simplify prescribing practices. The New Mexico Health Care Authority is currently seeking qualified healthcare professionals to serve on the combined Pharmacy and Therapeutics (P&T) and Drug Utilization Review (DUR) Committee. The P&T/DUR Committee plays a critical role in ensuring safe, effective, and evidence-based use of medications within the state’s healthcare programs. Members review clinical evidence, provide recommendations to the Medicaid CMO, and develop guidance on pharmaceutical policies that impact patient care statewide.
_____________________________________________________________________________________________
If you have any questions or comments about this agenda, please contact Cynthia Gustafson, Cynthia.gustafson@hca.nm.gov.
Return to Pharmacy Main Page
